Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

A flow cytometric study of c-erbB-3 expression in breast cancer

Lookup NU author(s): Dr Ian Brotherick, Dr Brian Shenton, Dr Brian Angus, Ian Waite, Professor Thomas Lennard

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

In order to assess the specificity of biotinylated anti-c-erbB-3 antibody, screening was performed on a series of tumour cell lines and lymphocytes. Staining was found to be consistent, with good reproducibility. Twenty-nine consecutive breast cancer samples were obtained from women treated with tamoxifen and undergoing elective mastectomy. Twenty-eight invasive ductal carcinomas and 1 DCIS were stained for c-erbB-3 expression: 2 were grade I (Bloom and Richardson), 15 grade II, and 11 grade III tumours, 1 being unclassified; 16 were axillary node positive and 10 node negative; in 2 cases no nodes were sampled. Tumours examined by flow cytometry were stained with cytokeratin FITC antibody and the cytokeratin-positive population gated. Using Mann-Whitney analysis no association was seen between c-erbB-3 expression and Bloom and Richardson grade or axillary node status. In the tumour samples c-erbB-3 expression was found to show an association with EGF-R (P = 0.021 r(2) = 0.16), PgR (P = 0.02, r(2) = 0.16), c-myc (P <0.0001, P = 0.5), c-jun (P = 0.001, r(2) = 0.4) and c-fos (P = 0.001, r(2) = 0.5) but not with c-erbB-2 (P = 0.2, r(2) = 0.06), ER (P = 0.4, r(2) = 0.02) or p53 1801 (P = 0.05, r(2) = 0.2). Expression of c-erbB-3 may not be an independent marker of prognosis, but it is associated with other markers of poor prognosis and early cellular events linked with aberrant growth and differentiation.

Publication metadata

Author(s): Brotherick I, Shenton BK, Angus B, Waite IS, Horne CHW, Lennard TWJ

Publication type: Article

Publication status: Published

Journal: Cancer Immunology, Immunotherapy

Year: 1995

Volume: 41

Issue: 5

Pages: 280-286

Print publication date: 01/11/1995

ISSN (print): 0340-7004

ISSN (electronic): 1432-0851

URL: http://dx.doi.org/10.1007/BF01517215

DOI: 10.1007/BF01517215

Altmetrics

Altmetrics provided by Altmetric

Share